Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants

Inclusion Criteria: * Age 8 weeks (56-63 days) at the time of first vaccination * Infants in good general health, eligible to be vaccinated according to the Polish national vaccination program. The same health criteria apply as used in well-baby clinics when a child receives a vaccination, e.g. also children with a small increase in temperature (\< 38.5° C) or with a common cold (runny nose etc) are seen as children with normal health. * The parent(s)/legally representative(s) have to be willing and able to allow their child to participate in the trial according to the described procedures * Presence of a signed informed consent in which the parent(s)/legally representative(s) have given written informed consent after receiving oral and written information (signature from one parent in case of single-parent family). Exclusion Criteria: * Any IPV or OPV dose * Known or suspected allergy against any of the vaccine components * History of unusual or severe reactions to any previous vaccination administration of plasma (including immunoglobulins) or blood products prior and during the study * Any vaccination less than 14 days before or after each vaccination with the IMP * History of any neurological disorder including epilepsy or febrile seizures * Any infectious disease at the time of screening and/or inclusion that might interfere with the results of the study * Present evidence of serious disease(s) demanding immunosuppressive medical treatment, like cytostatics and prednisolones, that might interfere with the results of the study * Any known or suspected primary or secondary immunodeficiency * Communication problems interfering in the study realization according to the judgment of the investigator * Bleeding disorders and use of anticoagulants * Premature birth (\<37 weeks) * Participation in another clinical trial